User profiles for J Wouter Jukema

Wouter Jukema

Professor of cardiology, Leiden University Medical Center, Leiden, the Netherlands
Verified email at lumc.nl
Cited by 211721

Restenosis after PCI. Part 1: pathophysiology and risk factors

JW Jukema, JJW Verschuren, TAN Ahmed… - Nature Reviews …, 2012 - nature.com
Restenosis is a complex disease for which the pathophysiological mechanisms have not yet
been fully elucidated, but are thought to include inflammation, proliferation, and matrix …

Late stent malapposition risk is higher after drug-eluting stent compared with bare-metal stent implantation and associates with late stent thrombosis

…, JWM Plevier, MJ Schalij, J Wouter Jukema - European heart …, 2010 - academic.oup.com
Aims Late stent malapposition (LSM) may be acquired (LASM) or persistent. LSM may play
a role in patients who develop late stent thrombosis (ST). Our objective was to compare the …

Statins and all-cause mortality in high-risk primary prevention: a meta-analysis of 11 randomized controlled trials involving 65 229 participants

…, S Erqou, P Sever, JW Jukema… - Archives of internal …, 2010 - jamanetwork.com
Background Statins have been shown to reduce the risk of all-cause mortality among individuals
with clinical history of coronary heart disease. However, it remains uncertain whether …

Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial

…, SM Cobbe, I Ford, A Gaw, M Hyland, JW Jukema… - The lancet, 2002 - thelancet.com
Background Although statins reduce coronary and cerebrovascular morbidity and mortality
in middle-aged individuals, their efficacy and safety in elderly people is not fully established. …

[HTML][HTML] Ezetimibe added to statin therapy after acute coronary syndromes

…, BS Lewis, TO Ophuis, JW Jukema… - … England Journal of …, 2015 - Mass Medical Soc
Background Statin therapy reduces low-density lipoprotein (LDL) cholesterol levels and the
risk of cardiovascular events, but whether the addition of ezetimibe, a nonstatin drug that …

Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials

…, JJ McMurray, DJ Freeman, JW Jukema… - The Lancet, 2010 - thelancet.com
Background Trials of statin therapy have had conflicting findings on the risk of development
of diabetes mellitus in patients given statins. We aimed to establish by a meta-analysis of …

[HTML][HTML] Alirocumab and cardiovascular outcomes after acute coronary syndrome

…, C Hanotin, RA Harrington, JW Jukema… - … England Journal of …, 2018 - Mass Medical Soc
Background Patients who have had an acute coronary syndrome are at high risk for recurrent
ischemic cardiovascular events. We sought to determine whether alirocumab, a human …

Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease

…, BD Horne, T Illig, C Iribarren, GT Jones, JW Jukema… - Nature …, 2011 - nature.com
We performed a meta-analysis of 14 genome-wide association studies of coronary artery
disease (CAD) comprising 22,233 individuals with CAD (cases) and 64,762 controls of …

Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum …

JW Jukema, AVG Bruschke, AJ van Boven… - Circulation, 1995 - Am Heart Assoc
Background Intensive lowering of serum cholesterol may retard progression of coronary
atherosclerosis in selected groups of patients. However, few data are available on the potential …

Diagnostic accuracy of 64-slice computed tomography coronary angiography: a prospective, multicenter, multivendor study

…, AM de Vos, F Pugliese, B Rensing, JW Jukema… - Journal of the American …, 2008 - jacc.org
Objectives : This study sought to determine the diagnostic accuracy of 64-slice computed
tomographic coronary angiography (CTCA) to detect or rule out significant coronary artery …